基本信息
浏览量:17
职业迁徙
个人简介
The research of Shaji Kumar, M.D., focuses on development of novel drugs for treatment of myeloma. Dr. Kumar's research team evaluates the in vitro activity of novel drugs that, based on their mechanisms of action, are likely to have activity in the setting of myeloma. Promising drugs are brought into the clinic through early-stage clinical trials in Phase I or II studies.
Dr. Kumar also evaluates novel combinations of different drugs to identify synergistic combinations that can result in better treatment responses and eventually better patient outcomes. His work on drug development is complemented by an active program studying the biology of myeloma, with a focus on the study of bone marrow microenvironment in multiple myeloma and how it influences the tumor cells, especially the increased bone marrow microvessels seen in myeloma. His clinical research focuses on outcomes of patients with myeloma and amyloidosis, especially high-risk disease.
研究兴趣
论文共 1781 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
HEMATOLOGICAL ONCOLOGYno. 1 (2024): e3222-e3222
Research squareno. 1 (2024): 1-7
Blood Cancer Journalno. 1 (2024): 1-6
Hematology/oncology clinics of North Americano. 2 (2024): 511-532
Acta haematologica (2023)
引用0浏览0WOS引用
0
0
Clinical Lymphoma Myeloma and Leukemiano. 3 (2023): 413-420
The Hematologistno. 2 (2023)
引用0浏览0引用
0
0
Genetics in Medicine Openno. 1 (2023): 100816
引用0浏览0引用
0
0
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023): S191-S191
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn